Trial Profile
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Epratuzumab cys SG3249 (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 16 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 08 Aug 2023 According to an ADC Therapeutics media release, Dose expansion in the Phase 1 trial in collaboration with MD Anderson Cancer Center is progressing and additional clinical trial sites have been selected.